Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SOD1 | P00441 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320330 | 0.84 | HIF1A (0.45) | MAOBHTTALDH1A1LMNA | |
| SCHEMBL30395305 | 0.83 | MAOB (0.56) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL1785290 | 0.83 | MAOB (0.56) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL30429412 | 0.83 | MAOB (0.56) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL307767 | 0.83 | MAOB (0.56) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL13883739 | 0.82 | MAOB (0.64) | MAOBRAB9AHTTL3MBTL1SOD1 | |
| SCHEMBL3393523 | 0.81 | MAOB (0.46) | MAOBRAB9AALDH1A1MRGPRX4GRM4 | |
| SCHEMBL7162438 | 0.80 | MAOB (0.62) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL1203917 | 0.78 | MAOB (0.60) | MAOBRAB9AHTTL3MBTL1SOD1 | |
| SCHEMBL14303721 | 0.78 | MAOB (0.60) | MAOBRAB9AHTTL3MBTL1SOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3852736-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020061117-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061116-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2018170165-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| EP-3174880-A1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016381-A1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-04 | — | — | WO | disclosed |
| EP-2935240-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2760845-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2014100695-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2009011655-A1 | SPLROPIPERIDINE COMPOUNDS, A PROCESS OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE TREATMENT OF AIRWAY DISEASES, INFLAMMATORY DISEASES, COPD OR ASTHMA | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011653-A1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES AND THEIR US IN THE SYNTHESIS OF SPIROPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008010765-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007005531-A2 | ALKENYLDIARYLMETHANES, FUSED ANALOGS AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1659121-A1 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005100301-A1 | 2-ARYLOXYETHYL GLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |